INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Hims & Hers Health, Inc. - HIMS

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. regarding potential securities fraud or unlawful business practices [1] - Novo Nordisk has discontinued its partnership with Hims & Hers due to non-compliance with legal regulations concerning the sale of compounded drugs, which has raised patient safety concerns [3] - Following the announcement of the partnership termination, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3] Company Overview - Hims & Hers Health, Inc. is publicly traded on the NYSE under the ticker symbol HIMS [1] - The company has faced scrutiny regarding its business practices, particularly in relation to the sale of compounded drugs [3] Legal and Regulatory Context - The investigation by Pomerantz LLP suggests potential legal challenges for Hims & Hers, which may impact investor confidence [1] - Novo Nordisk's decision to end the partnership highlights regulatory compliance issues that could affect Hims & Hers' operations and reputation [3]